Nanopharma Cerulean Advances Cancer Particle, Looks Ahead To siRNA
• By Pharmaceutical Approvals Monthly
Nanotech platform company Cerulean Pharma Inc. has a high-quality problem. The Cambridge, Mass., start-up is poised to take its lead candidate into Phase IIb cancer trials, but the young company must choose among several cancer types in which the nanoparticle shows go-ahead activity
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
